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Summary
 
It is widely accepted that cellular immune responses are induced by CD4
 
1
 
 T helper 1 (Th1)
cells secreting interleukin (IL)-2 and interferon (IFN)-
 
g
 
. Tumor immunity is often mediated
by cytotoxic T lymphocytes (CTLs) whose activation is supported by Th1 cytokines. Since IL-4
directs Th2 development and has been shown to inhibit Th1-dominated responses, we as-
sumed that IL-4–deficient (IL-4
 
2/2
 
) mice would develop vigorous CTL-mediated tumor im-
munity compared with IL-4–competent (IL-4
 
1/1
 
) mice. Surprisingly, IL-4
 
2/2
 
 mice were se-
verely impaired to develop tumor immunity to both a mammary adenocarcinoma line and a
colon carcinoma line. The lack of tumor immunity in IL-4
 
2/2
 
 mice was associated with re-
duced IFN-
 
g
 
 production, diminished levels of tumor-reactive serum IgG2a, and undetectable
CTL activity, indicating a defective Th1 response in the absence of endogenous IL-4. Anti–IL-4
monoclonal antibody blocked tumor immunity in IL-4
 
1/1
 
 mice when administered at the time
of immunization but not at the time of challenge. Additionally, tumor immunity could be in-
duced in IL-4
 
2/2
 
 mice, if IL-4 was provided by gene-modified cells together with immunizing
tumor cells. These results demonstrate that tumor immunity requires IL-4 in the priming phase
for the generation of effector cells rather than for their maintenance and exclude secondary, de-
velopmental defects in the “knockout” strain. Together, our results demonstrate a novel and
previously unanticipated role of IL-4 for the generation of Th1-associated, CTL-mediated tu-
mor immunity.
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M
 
ost experimental tumors and probably many human
tumors express antigens against which an immune
response can be induced (1). In mice it has been shown
clearly that such antigens can serve as rejection antigens, if
the mice are immunized with tumor cells in an immuno-
genic, nontumorigenic form (2) or with tumor antigens
themselves (3) and subsequently challenged with a tumori-
genic dose of that tumor. Recent results from different
groups have shown that tumor immunogenicity is defined
operationally rather than absolutely and that it can be en-
hanced in various ways. Tumor immunity can be induced,
at least in some models, by tumor cells engineered to ex-
press certain cytokines or the T cell costimulatory molecule
B7 (4) or, more simply, by the use of adjuvants (5), re-
peated immunizations (6), or with larger numbers of tumor
cells (7). The cellular requirements for induction of tumor
immunity seem to be quite similar regardless of the type of
immunization. Rejection of MHC class I
 
1
 
, class II
 
2
 
 tumors
(like the ones used in this study) often requires CD8
 
1
 
CTLs whose activation (8), and in some models mainte-
nance (3), depends on help by CD4
 
1
 
 T cells. To provide
help, CD4
 
1
 
 T cells must first be activated, which requires
tumor-derived antigens to be taken up, processed, and pre-
sented by an MHC class II
 
1
 
 APC. The fact that activation
of CTLs specific to minor H antigens (9) or surrogate tu-
mor antigens (10, 11) similarly depends on host APCs sug-
gests that the same APC presents antigens to CD4
 
1
 
 and
CD8
 
1
 
 T cells by MHC class II and class I molecules, re-
spectively (12). The close proximity of CD4
 
1
 
 and CD8
 
1
 
 T
cells recognizing antigens on the same APC would be
compatible with the assumption that help by CD4
 
1
 
 to
CD8
 
1
 
 T cells occurs by providing cytokines that are sup-
posed to act on a short distance, e.g., in the same lymph
node. However, CD4
 
1
 
 T cell help for CTL generation
must not necessarily consist in cytokine supply. Recently, it
has been demonstrated that signaling through CD40 on
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2
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APCs can replace the requirement for CD4
 
1
 
 T cells during
CTL generation (13–15).
CD4
 
1
 
 T cell lines can be divided into two subpopula-
tions, Th1 and Th2, based on the profile of secreted cyto-
kines (16). Th1 cells predominantly produce IL-2 and IFN-
 
g
 
and are associated with cellular immune responses such as
delayed hypersensitivity or differentiation of CD8
 
1
 
 T cells
into CTLs (17). They also induce class switch in B cells to
IgG2a. Th2 cells preferentially produce cytokines such as
IL-4 and IL-10, and are associated with a humoral immune
response, e.g., inducing class switch to IgE and IgG1. Th1
and Th2 cells have been implicated in different models of
infectious disease or autoimmunity with disease susceptibil-
ity or protection, respectively (18). IFN-
 
g
 
 production by
Th1 cells inhibits the maturation of Th2 cells (19). Con-
versely, IL-4 production by Th2 cells suppresses the gener-
ation of Th1 cells (20). It is important to note that the
cross-inhibitory effects of IL-4 and IFN-
 
g
 
 have been dem-
onstrated mainly in vitro or in the late phase of the im-
mune response to chronic antigen exposure (18). The deci-
sion whether an immune response is directed to Th1 or
Th2 seems to depend on a number of variables (e.g., nature
of the antigen, amount of antigen, type of APC, local cy-
tokine milieu, and mouse strain) (21); however, it appears
to be made rapidly. Thus, antigen-specific IgG2a or IgG1
can be detected within 5 d of immunization in a Th1- or
Th2-inducing fashion (22). The cytokine requirements for
induction of the Th1 pathway in the early phase are not
completely understood. However, a few reports have chal-
lenged the assumption of a simple inverse relationship be-
tween IL-4 and IFN-
 
g
 
 production in vivo. Transgenic ani-
mals constitutively overexpressing small amounts of IL-4
have elevated, not decreased, IFN-
 
g
 
 mRNA levels (23). In
an in vitro
 
 
 
rat model of activated T cell blasts, IL-4–stimu-
lated IFN-
 
g
 
 synthesis early in the culture but inhibited the
development of IFN-
 
g
 
–producing T cells (24). Kamogawa
et al. showed, in a transgenic mouse model that allowed
ablation of IL-4 producing cells, that IFN-
 
g
 
 producing
cells were also concomitantly deleted (25). The interpreta-
tion was that Th1 and Th2 cells were derived from a com-
mon precursor. The question whether early IL-4 expres-
sion is required for the generation of Th1 cells could not be
addressed with these mice. Using BALB/c IL-4
 
2/2
 
 mice
along with IL-4 reconstitution experiments, we show that
the absence of IL-4 in the priming phase results in disabled
Th1 generation and CTL development and defective tu-
mor immunity.
 
Materials and Methods
 
Mice.
 
BALB/c mice were purchased from Bomholtgaard
Breeding & Research Centre, Denmark. IL-4-deficient mice (IL-
4
 
2/2
 
) were generated by targeted disruption of the IL-4 gene in
embryonic stem cells derived from BALB/c mice (26) and pro-
duced in a manner such that they can be considered IL-4–con-
genic to BALB/c. The deficiency of the IL-4 gene was con-
firmed by PCR of tail DNA as previously described (27). All
mice used in the experiments were 6–12-wk-old and were sex
matched. Heterozygous control littermates were also included in
some vaccination experiments and showed no significant differ-
ences in tumor rejection compared with BALB/c mice that were
commercially obtained (data not shown).
 
Cell Lines.
 
TS/A is a spontaneous mammary adenocarci-
noma cell line (28) and CT-26 is an 
 
N
 
-nitroso-
 
N
 
-methylure-
thane–induced colon carcinoma (29), both syngeneic to BALB/c.
Both tumor cell lines express MHC class I but not MHC class II
molecules (data not shown). NIH-3T3-IL-4 cells were generated
by transfection of NIH-3T3 with an expression vector encoding
the cDNA coding region of murine IL-4. 10
 
6
 
 NIH-3T3-IL-4
cells produce 130 U/ml within 24 h of culture (data not shown).
Biological activity of IL-4 was determined by a proliferation assay
with the IL-4–dependent cell line CT.4S (30). 1 U of IL-4 was
defined as the amount of IL-4 required to obtain half-maximal
proliferation. YAC-1 is an MHC-deficient NK cell target cell
line (31). All cell lines were cultured in RPMI-1640 with 10% FCS.
 
Tumor Vaccination Experiments.
 
For vaccination experiments,
cells of the indicated lines were washed twice in Dulbecco’s PBS,
irradiated (100 Gy), and injected subcutaneously in a vol of 0.2 ml
Dulbecco’s PBS in the middle of the left flank. 2 wk after immu-
nization, viable tumor cells were injected contralaterally. Mice
bearing tumors of 1 cm in diameter were scored as tumor posi-
tive. Tumor incidence is expressed as percentage of tumor-free
mice.
 
Serum Ig Detection and Analysis of Tumor-specific IgG2a.
 
Mice
were immunized twice with 10
 
6
 
 irradiated (100 Gy) CT-26 cells
on days 0 and 21. Serum Ig levels before and 14 d after the sec-
ond immunization were determined by ELISA. Relative serum
levels of IgG1 and IgG2a were measured using the Ig isotyping
kit according to the manufacturer’s recommendation (PharMin-
gen, Germany). For IgE detection, a pair of commercially avail-
able mAbs and the appropriate mouse IgE standard were used (all
from PharMingen). For detection of tumor-reactive IgG2a, 10
 
6
 
CT-26 cells were incubated with sera (1:20 dilutions), rat anti–
mouse IgG2a (PharMingen), and PE F(ab
 
9
 
)
 
2
 
 goat anti–rat Ig (Im-
munotech, France), followed by flow cytometric analysis using
Coulter EPICS-XL (Coulter Electronics GmbH, Germany). Fold
above background was determined by dividing the median fluo-
rescence of a stained sample by that of cells treated identically but
without serum.
 
Cellular Cytotoxicity.
 
For the generation of CT-26–specific
CTLs, mice were immunized twice with 10
 
6
 
 irradiated (100 Gy)
CT-26 cells on days 0 and 21. 14 d after the second injection,
single cell suspensions of splenocytes were prepared and red
blood cells were removed by NH
 
4
 
Cl treatment. Splenocytes
were cultured at 2 
 
3 
 
10
 
6
 
/ml with irradiated (100 Gy) CT-26
cells at a responder/stimulator cell ratio of 30:1 in RPMI-1640
plus 10% FCS, penicillin/streptomycin, MEM, 2-ME (50 
 
m
 
M),
and 50 U/ml IL-2 (Boehringer Mannheim, Germany). After 5 d
of culture, responder cells were harvested, washed twice, and in-
cubated with 
 
51
 
Cr (1 mCi/ml; NEN)-labeled CT-26 or YAC-1
cells at different E/T cell ratios. After an incubation period of
4.5 h, supernatants were assayed for radioactivity on a gamma
counter (Top Count; Packard). The percentage of specific lysis
was calculated as [(sample cpm 
 
2 
 
spontaneous cpm) / (maximal
cpm 
 
2 
 
spontaneous cpm)] 
 
3 
 
100%. Spontaneous release was
 
,
 
19%.
 
IFN-
 
g
 
 Detection.
 
For IFN-
 
g
 
 detection, mice were immu-
nized as described above. Splenocytes of immunized mice were
cultured in 24-well plates at 2 
 
3 
 
10
 
6
 
/ml in the presence of Con
A (2.5 
 
m
 
g/ml) for 3 d and supernatants were collected. CD8
 
1
 
 T
cells were depleted by negative selection with anti-CD8a (53-
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6.7), followed by separation using magnetic beads coated with
sheep anti–rat IgG (Dynal A.S., Norway). Depletion was checked
by cytofluorimetric analysis using PE-conjugated anti-CD8a (53-
6.7) (PharMingen). Culture supernatants were assayed for IFN-
 
g
 
by ELISA using commercially available reagents (all from Phar-
Mingen). The detection limit was 30 pg/ml.
 
In Vivo Neutralization of IL-4.
 
Groups of IL-4
 
1/1
 
 mice were
immunized with 5 
 
3 
 
10
 
5
 
 irradiated (100 Gy) TS/A cells and
challenged 14 d later with 10
 
5
 
 of viable TS/A cells. Treatment
with the IL-4–neutralizing mAb 11B11 was done by intraperito-
neal injections of 4 mg in 0.2 ml every 2 d from day 
 
2
 
2 to 6 of
immunization or challenge, respectively. Animals of the control
group received Dulbecco’s PBS.
 
Results
 
Induction of Tumor Immunity Is Impaired in IL-4
 
2/2
 
 Mice.
 
The ability to induce tumor immunity with nonproliferat-
ing tumor cells can depend on several variables, one of
which is the number of tumor cells. To titrate the number
of immunizing cells capable of inducing tumor immunity
against the mammary adenocarcinoma TS/A, IL-4
 
1/1
 
 and
IL-4
 
2/2
 
 mice were immunized with increasing numbers of
irradiated cells. 2 wk later, the mice were challenged with a
constant number of TS/A cells sufficient to give rise to tu-
mors in 100% of naive mice (Fig. 1, a–c). At the lowest im-
munization dose, 100% of IL-4
 
1/1
 
 and IL-4
 
2/2
 
 mice devel-
oped tumors. With increasing vaccination doses, IL-4
 
1/1
 
mice rejected the challenge tumor, whereas IL-4
 
2/2
 
 mice
were consistently less protected. These results were con-
firmed with a second tumor (CT-26; Fig. 1, d–f). 100% of
challenge tumors grew in mice of both genotypes after im-
munization with the lowest cell number of CT-26. In-
creasing immunization doses induced protection in the ma-
jority of IL-4
 
1/1
 
 
 
mice, whereas almost all IL-4
 
2/2
 
 mice
were unable to reject the challenge tumor. The defect of
IL-4
 
2/2
 
 mice to reject the challenge tumor was not due to
 
generally enhanced tumor growth, because TS/A and CT-
26 cells grew with similar kinetics in naive IL-4
 
1/1
 
 and IL-
4
 
2/2
 
 mice (Fig. 2). Therefore, IL-4 is required for the gen-
eration of protective tumor immunity.
 
IL-4
 
2/2
 
 Mice Have a Defective CTL Response.
 
Immuni-
zation with CT-26 induces tumor-reactive CTLs that are
able to confer protection against challenge tumors (32). To
find whether the defective tumor immunity in IL-4
 
2/2
 
mice was associated with reduced CTL activities, IL-4
 
1/1
 
and IL-4
 
2/2
 
 mice were immunized with CT-26 cells and
tumor-specific lysis was measured. CTL activity of IL-4
 
2/2
 
splenocytes was undetectable, whereas splenocytes of IL-
4
 
1/1
 
 mice contained substantial CTL activity (Fig. 3). Cy-
tolytic activity against the NK target YAC-1 was negligible
in spleen cells from both mouse strains, suggesting that lysis
of CT-26 by IL-4
 
1/1
 
 CTLs was specific. Additionally, im-
munization with 
 
b
 
-galactosidase–expressing TS/A cells re-
sulted in clearly reduced 
 
b
 
-galactosidase-specific CTL-activ-
ity in IL-4
 
2/2
 
 mice (data not shown).
 
Tumor Immunity in IL-4
 
1/1
 
 Mice Is Associated with a Th1
Response.
 
Changes in serum Ig isotype levels are an indi-
Figure 1. Generation of tumor immunity
is impaired in IL-42/2 mice. IL-41/1 (j)
and IL-42/2 mice (s) were immunized sub-
cutaneously with irradiated TS/A (a–c) or
CT-26 (d–f) with cell numbers as indicated. 2
wk later, mice were challenged contralater-
ally with 105 TS/A (a–c) or 106 CT-26 cells
(d–f). Numbers of mice per group were 5
(a, b, d) or 15–18 (c, e, f; combined results
from two to three experiments).
Figure 2. Tumor growth does not differ in naive IL-41/1 (j) and IL-
42/2 mice (s). Animals were injected subcutaneously with 105 viable
TS/A cells (a; n 5 6) or 106 viable CT-26 cells (b; n 5 5). The tumor size
was measured twice a week.
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cation for ongoing Th1 or Th2 responses in vivo. We have
shown that immunity to TS/A cells requires CD41 T cells
to be present during the priming phase (8). Similarly,
immunization with recombinant vaccinia virus encoding
b-galactosidase elicited maximal therapeutic effects to CT-
26–b-galactosidase cells through the involvement of CD41
T cells (33). Therefore, we analyzed total serum levels of
different Ig isotypes before and after immunization of IL-
41/1 mice with CT-26 to evaluate if tumor immunity was
associated with a dominant cytokine response (Fig. 4 a).
Amounts of IgE and IgG1 remained largely unaltered,
whereas IgG2a was significantly increased. To detect IgG2a
antibodies reacting with tumor cells, CT-26 cells were
stained with the same sera and the binding efficiency was
measured by FACS® analysis. As shown in Fig. 4 b, sera of
immunized mice showed, to varying extents, elevated
amounts of tumor-reactive IgG2a compared with sera of
naive mice indicating IFN-g production in response to
CT-26 cells. These data show that the immunization of IL-
41/1 mice with a sufficient amount of CT-26 cells initiated
a typical Th1-associated response.
IL-42/2 Mice Fail to Generate a Th1-associated Antitumor
Response. Next, Ig levels in IL-42/2 mice before and after
injection of irradiated CT-26 cells were measured to evalu-
ate if impaired T helper cell responses might account for
reduced tumor immunity in IL-42/2 mice (Fig. 5 a). As re-
ported previously, IgE is undetectable in naive IL-42/2
BALB/c mice (27) and was not induced by the injection of
CT-26. The amount of IgG1 was not significantly altered
in response to CT-26. Surprisingly, serum concentrations
of IgG2a were only slightly enhanced after vaccination, al-
though basal levels of IgG2a were elevated in comparison
to IL-41/1 mice. These results indicate a reduced IFN-g
production upon immunization in the absence of endoge-
nous IL-4 (Fig. 4). To confirm this assumption, we cul-
tured splenocytes of immunized IL-41/1 and IL-42/2 mice
in the presence of Con A and measured IFN-g in culture
supernatants (Fig. 5 b). Spleen cells of IL-42/2 mice pro-
duced twofold lower amounts of IFN-g than those of
IL-41/1 mice. Similar results were obtained with CD81-
depleted spleen cells. These data are in accordance with the
measurements of serum Ig isotypes, again suggesting that
endogenous IL-4 is required for the induction of a Th1 an-
titumor immune response.
The Establishment of Tumor Immunity Requires IL-4 Produc-
tion during the Priming Phase. IL-4 is produced by naive
CD41 T cells under Th1 polarizing conditions in vitro
within the first 24 h of antigen contact (34). Therefore, we
questioned at which time IL-4 was required for the genera-
tion of tumor immunity. IL-4 was neutralized in IL-41/1
mice by anti–IL-4 mAb during either the immunization or
the challenge period. After immunization and challenge
with TS/A cells, 50% of control mice but none of the ani-
mals treated with the anti–IL-4 mAb during the immuniza-
tion phase rejected the challenge tumor (Fig. 6). IL-4 neu-
tralization during the challenge phase did not impair tumor
rejection. In fact, fewer mice developed a challenge tumor,
the significance of which is not clear. These data indicate
that memory effector cells do not require IL-4 to exert
their tumoricidal activity, although their development is
dependent on early IL-4 production.
Exogenous IL-4 Restores Tumor Immunity in IL-42/2 Mice.
The data presented thus far do not clearly exclude that
unknown developmental defects in IL-42/2 mice, such as
reduced precursor frequencies of potential tumor reactive
lymphocytes, rather than the absence of IL-4 during the
priming phase, diminished vaccination efficiencies. To ad-
dress this, IL-42/2 mice were immunized with different
doses of CT-26 cells mixed with 106 IL-4–secreting NIH-
3T3-IL-4 cells. As controls, IL-42/2 mice were injected
with identical doses of CT-26 and parental, non-IL-
Figure 3. The generation of
cytotoxic T cells is impaired in
IL-42/2 mice. IL-41/1 (squares)
and IL-42/2 mice (circles) were
immunized twice subcutane-
ously at day 0 and day 21 with
106 irradiated CT-26 cells. 2 wk
after the second injection (day
35), spleen cells were restimu-
lated in vitro with CT-26 cells.
After 5 d of culture, CTL activi-
ties of IL-41/1 and IL-42/2 splenocytes were measured in a 4.5-h Cr-
release assay. Lysis of CT-26 (filled symbols) and YAC-1 cells (open sym-
bols) is shown.
Figure 4. Tumor immunity in IL-41/1
mice is associated with a Th1 response. IL-
41/1 mice were immunized subcutaneously
at day 0 and day 21 with 106 irradiated CT-
26 cells. (a) Relative amounts of the indi-
cated Ig subtypes before (day 0) and 14 d af-
ter the second immunization (day 35) in
sera of individual IL-41/1 mice were deter-
mined by ELISA. (b) Binding of serum
IgG2a to CT-26 cells is shown for the same
sera as in panel a. Fold above background
fluorescence was calculated by dividing the
median fluorescence of a stained sample by
the median fluorescence of a sample incu-
bated only with the primary and secondary
antibody. Bold lines represent mean values
for each experimental group.
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4-secreting NIH-3T3. 2 wk later, mice were challenged
with CT-26 cells and tumor incidence was measured. De-
pending on the number of CT-26 cells used for immuniza-
tion, 40–70% (Fig. 7, a and b, respectively) of mice devel-
oped protective tumor immunity after immunization in the
presence of exogenous IL-4, whereas none of the control
animals was protected. These results show that tumor im-
munity can be induced in IL-42/2 mice, as long as IL-4 is
provided during the immunization phase. As demonstrated
for IL-41/1 mice (Fig. 1), protection efficiency in IL-42/2
mice could also be modulated by the amount of antigen
used for immunization. Therefore, these experiments sug-
gest that IL-42/2 lymphocytes are functionally intact and
emphasize the necessity of IL-4 during the T cell priming
stage for the induction of tumor immunity.
Discussion
We have shown that IL-42/2 mice have a severe defect
in the development of tumor immunity. Furthermore, the
absence of tumor immunity in IL-42/2 mice was associated
with the absence of a Th1 response to the tumor as shown
by reduced serum IgG2a levels and IFN-g production. In
addition, we showed that IL-4 was required for the induc-
tion but not for the maintenance of tumor immunity. To
understand this unexpected role of IL-4, the sequence of
events leading to tumor immunity needs to be considered.
Antigens derived from the immunizing tumor cells which
are MHC class I1/II2 must be taken up and processed by
host APCs and presented by MHC class I and class II mol-
ecules to CD81 and CD41 T cells, respectively. Because
CD41 T cells are critical for the development of tumor im-
munity, the initial event is the activation of CD41 T cells,
which provide help for activation of CD81 CTLs (3, 8).
Like IL-4, CD41 T cells are necessary in the priming
phase. In the TS/A model, we have shown previously that
once CTLs have been generated, CD41 T cell depletion
(at the time of challenge) did not impair CTL mediated tu-
mor rejection (8). Therefore, it is likely that the defective
CTL response in IL-42/2 mice is the result of defective
help by Th1 cells. This help has been explained previously
by providing cytokines to CTLs, probably Th1 cytokines
like IL-2 or IFN-g (17). Recently, however, it has been
shown that CD41 T cell help for CTL activation does not
consist of a direct interaction between CD41 and CD81 T
cells but rather by activation of APCs, perhaps dendritic
cells (13–15). The cross-talk between CD41 T cells and
APCs is mediated by CD40–CD40 ligand interaction and
T cell help for CTL generation can be replaced by in vivo
application of an agonistic antibody that acts on APCs
other than B cells (15). This mechanism not only obviates
the need of CD41 and CD81 T cells to meet each other at
the same APC but also the need of Th1 cytokines for CTL
generation. It is possible that a similar mechanism is opera-
tive in our tumor models, a possibility that is supported by
the finding that IL-42/2 mice can mount an undiminished
CTL response to some viral antigens (35), which at least
partially occurs independently of CD41 T cell help (36,
37). Th1-independent CTL responses to viral antigens cor-
relate with the observation that viruses can directly infect
Figure 5. Decreased tumor immunity in
IL-42/2 mice is associated with an impaired
Th1 response. (a) Relative amounts of the
indicated Ig subtypes were determined by
ELISA before (day 0) and 14 d after the sec-
ond immunization (day 35) with 106 CT-26
cells. Each symbol represents serum Ig levels
of individual animals and bold lines repre-
sent mean values for each experimental
group. (b) IFN-g production by total and
(c) CD81-depleted splenocytes of IL-41/1
(white bars) and IL-42/2 (gray bars) mice
after immunization with CT-26 was com-
pared. Spleen cells obtained 14 d after the second immunization with 106 CT-26 cells (day 35) were cultured at 2 3 106/ml in the presence of 2.5 mg/ml
Con A for 3 d. Amounts of IFN-g in culture supernatants were determined by ELISA. n.d., not detectable.
Figure 6. Generation of tu-
mor immunity requires IL-4
during priming phase. IL-41/1
mice were immunized with 5 3
105 irradiated TS/A cells and
challenged 2 wk later with 105
TS/A cells. IL-4 was neutralized
either during immunization (d,
n 5 5) or challenge phase (j,
n 5 5) by intraperitoneal injec-
tion of mAb 11B11 at days 22,
0, 2, 4, and 6 of immunization or challenge, respectively. Mice of the
control group (h, n 5 10) were treated with PBS.
Figure 7. Exogenous IL-4 during immunization phase restores tumor
immunity in IL-42/2 mice. Groups of IL-42/2 mice were immunized sub-
cutaneously with the indicated numbers of irradiated CT-26 cells, which
were mixed with either 106 NIH-3T3 (s) or 106 NIH-3T3-IL-4 (d) cells.
Groups of 5 (a) or 10 mice (b) received the respective mixtures of cells. 2
wk later, mice were challenged contralaterally with 106 CT-26 cells.
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dendritic cells. Therefore, at the present time we cannot
distinguish whether IL-4 (which is produced for a short pe-
riod under Th1-polarizing conditions, see below) acts on
the APC or the CD41 T cells, or directly contributes to
CTL generation during priming.
Although our results apparently contradict the Th1/Th2
paradigm, they do not if the time of IL-4 activity that is re-
quired for development of a Th1 response is considered.
The inhibitory effect of IL-4 on Th1 development has
been most clearly observed in vitro under conditions of
prolonged addition of exogenous IL-4 or in vivo under
conditions of chronic antigen exposure (18). Our results do
not exclude the possibility that IL-4 has opposing effects in
later stages of an antitumor response, e.g., in tumor-bearing
animals. However, the fact that the development of a Th1
response and concomitant tumor immunity requires IL-4 at
the time of immunization only (when T cell priming
should happen) is reminiscent to the finding that CD41 T
cells cultured under Th1-polarizing conditions express IL-4
for the first 24 h (34). Also, the artificial expression of IL-4,
either by tumor cells transfected to secrete IL-4 or in a
transgenic mouse model, leads to induction of IFN-g in
vivo, in both T cell–competent and –deficient mice (23,
38). The importance of IFN-g for the development of
T cell–dependent tumor immunity (39) and for tumor
growth inhibition of IL-4–secreting tumors has been dem-
onstrated (38). Recently, it has been shown that IL-42/2
mice are impaired to resolve Candida albicans in the late
stage of infection, which has been explained by the missing
IL-4 to induce neutrophils for IL-12 production and subse-
quent Th1 development (40). The fact that the induction
of an antitumor response induced by tumor cell–produced
IL-4 is critically dependent on neutrophils (41) raises the
possibility that a similar mechanism is operating during the
generation of tumor immunity, although CTLs to C. albi-
cans had not been measured.
The immunogenicity of tumor cells depends on a num-
ber of factors related to the host, e.g., the inhibitory effect
of B cells (8), or to the tumor, e.g., the expression of im-
munosuppressive cytokines (42) or the amount of tumor
cells used for immunization (Fig. 1). The failure to induce
tumor immunity with low numbers of tumor cells could
mean that it is simply the limiting amount of tumor-
derived antigens available for the appropriate APCs, yet IL-4
is produced in a manner unrelated to the immunizing
tumor cells (43), or that a certain number of tumor cells is
required to induce IL-4. We favor the latter assumption,
because Bosco et al. showed in the TS/A tumor model that
in mice challenged with a low number of viable tumor cells
which did not lead to a measurable antitumor response that
tumor immunity could be induced by IL-4 injection
around the tumor-draining lymph node where T cell prim-
ing probably occurs (44). IL-4 was injected for a period
of 10 d, which is comparable to the estimated time of
IL-4 production by the NIH-3T3-IL-4 cells, which when
added to the immunizing tumor cells restored tumor im-
munity in IL-42/2 mice (Fig. 7). It is important to note that
very low amounts of recombinant IL-4 (0.1 pg/d) were
most effective (44), showing that not only the time point
but also the amount of IL-4 required for induction of tu-
mor immunity is critical. We also show that the lack of IL-4
is not compensated for by other cytokines such as IL-13
(45, 46) for the generation of tumor immunity. Our results
are surprising because a number of studies in other experi-
mental models with IL-42/2 mice showed that IL-4 was
not necessary for a normal immune response, e.g., against
parasites (47), viruses (35), or even diminished immune re-
actions, e.g., in retrovirus-induced immunodeficiency syn-
drome (MAIDS; reference 48). Whether this difference is
due to Th-dependent CTL generation often required for
tumor immunity remains to be established. In conclusion,
our study reveals a novel role of IL-4 for the generation of
tumor immunity that contributes to a better mechanistic
understanding as a rationale for immunotherapy.
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